Cargando…
Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient
Autores principales: | McCord, Matthew, Lukas, Rimas V, Amidei, Christina, Demars, Nathan, Gelb, Arnold, Buck, Jill, Sachdev, Sean, Feldman, Alexander, Tate, Matthew, Dixit, Karan, Brat, Daniel J, Jennings, Lawrence, Horbinski, Craig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262637/ https://www.ncbi.nlm.nih.gov/pubmed/34250480 http://dx.doi.org/10.1093/noajnl/vdab045 |
Ejemplares similares
-
Markedly prolonged disease course, with breakthrough seizures, in a glioma with an isolated IDH1 mutation
por: Drumm, Michael, et al.
Publicado: (2022) -
Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
por: File, Danielle M., et al.
Publicado: (2020) -
Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary
por: Martinez, Francisco, et al.
Publicado: (2021) -
Infantile ZFTA Fusion–Positive Tumor of the Posterior Fossa: Molecular Tumor Board
por: Paulson, Vera A., et al.
Publicado: (2023) -
Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
por: Hamdan, Diaddin, et al.
Publicado: (2023)